Article Information
History
- December 21, 2020.
Article Versions
- Version 1 (December 4, 2020 - 15:09).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Peter Vernon van Heerden, MD1,
- Avraham Abutbul, MD2,
- Sigal Sviri, MD2,
- Eitan Zlotnik, MD3,
- Ahmad Nama, MD4,
- Sebastian Zimro, MD1,
- Raja el-Amore, BSc3,
- Yehudit Shabat, MSc5,
- Barak Reicher, PhD5,
- Batla Falah, MD6 and
- Dror Mevorach, MD3,7,*
- 1General Intensive Care Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- 2Medical Intensive Care Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- 3Rheumatology and Rare Disease Research Center, The Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center and School, Jerusalem, Israel
- 4Department of Emergency Medicine, Hadassah-Hebrew University Medical Center and School, Jerusalem, Israel
- 5Enlivex Therapeutics Ltd., Ness-Ziona, Israel
- 6Department of Cardiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- 7Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- ↵* Corresponding author: Prof. Dror Mevorach, Rheumatology and Rare Disease Research Center, The Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center and School, Kiryat Hadassah P.O.B 12000, Jerusalem 9112001, Israel. Phone: +972-2-6777317; email: mevorachd{at}hadassah.org.il
Posted December 21, 2020.
